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Abstract 
Teicoplanin has a long serum half-life, and therefore it takes time to reach a steady-state 
concentration.  An initial loading procedure has been recommended for teicoplanin to 
enable prompt reaching of  the optimal serum trough level (10-15μg/ml).  However, 
the dose of teicoplanin that should be administered to patients with varying renal 
function levels remains inconclusive.  In this study, we monitored the serum 
concentrations of teicoplanin in the patients with methicillin-resistant Staphylococcus 
aureus (MRSA) pneumonia and compared different teicoplanin serum concentrations 
and their clinical efficacy, investigating the significance of the mean dose administered 
during the initial 3 days.   The study included 48 patients with MRSA pneumonia.  
The peak and trough concentrations of teicoplanin were determined utilizing a 
fluorescence polarization immunoassay and a two-compartment Bayesian population 
model.   Teicoplanin was given at a loading dose of 400 or 800 mg on the first day, 
followed by maintenance doses of 200 or 400 mg.  The mean initial dose (MID) over 
the first 3 days was calculated as (loading dose + dose for 2nd day + dose for 3rd day) / 
3.  Patients with MID of 266.7 mg or less (400mg for loading, 200mg over the 2nd and 
3rd day) did not have a trough level that exceeded 10μg/ml at the point before the 
injection on the 4th day.  Even in patients with hemodialysis (HD), an MID of 266.7 
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mg was not enough to provide a trough level of 10μg/ml.  Patients with an MID than 
533.3mg had significantly elevated trough levels, showing better outcomes.  A 
multiple regression formula for predicting trough level before the fourth day of 
administration is given as: 0.034 + 0.030 x (MID, mg) - 0.057 x creatinine clearance 
(Ccr; ml/min).   These findings suggest that 800 mg as an initial dose, followed by 
400 mg maintenance doses over the following 2 days, makes it possible to safely attain 
an optimal trough level, even in the patients with HD. 
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Introduction 
     The glycopeptide antibiotics, vancomycin and teicoplanin are being used in 
Japan only for patients with methicillin-resistant Staphylococcus aureus (MRSA) 
infections, while they are widely employed in other countries for gram-positive strain 
infections, in particular for severe or multi drug-resistant infections.  Teicoplanin 
possesses characteristic advantages over vancomycin such as its prolonged serum 
half-life, its postantibiotic effect, and a lower frequency of nephrotoxicity or red man 
syndrome 1).  However, teicoplanin needs a loading dose to enable a prompt rise in 
serum concentration, but the optimal loading dose is not known.  In this context, we 
undertook a retrospective study, monitoring teicoplanin serum concentrations, 
comparing the results with different concentrations for efficacy and toxicity.   
 
Patients and Methods 
Subjects 
     Serum and sputum samples and chest radiographs were obtained for 48 
consecutive patients (mean age, 74.3±11.5 years; 38 men and 10 women) who were 
given a diagnosis of MRSA pneumonia.  The diagnosis was based on all the following 
findings: fever over 37.5 ℃, cough, purulent sputum, significantly positive cultures of 
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MRSA in the sputum, an image of the Staphylococcus englobed in the Gram's stain of 
expectorated mucus, newly developed infiltrative shadows on chest X-ray films, 
leukocyte counts beyond 8,000/μl, and positive for C-reactive protein (CRP) or 
elevation of erythrocyte sedimentation rate (ESR).  Subjects with suspected mixed 
infections were excluded from the study.   Of the 48 patients, 6 patients were receiving 
hemodialysis (HD).  
 
Measurement of teicoplanin concentration in serum 
     Following the recommended regimen that is used in Japan, a loading dose of 200 
- 400 mg of teicoplanin, twice a day, was adminitstered to the patient on the first day, 
and then teicoplanin for maintenance was given once a day at a dose of 200-400 mg.   
No other antimicrobials were used during the study.  In this study, blood samples were 
taken at the following three points: (i) just before the injection on the 4th day, (ii) 2h 
after the administration on the 4th day, and (iii) just before the treatment on the 5th day.  
These points correspond to the trough level on the 4th day (Cpre), the peak level on the 
4th day (C1), and the trough level on the 5th day (C2), respectively. 
     The serum concentrations of teicoplanin were determined by utilizing a  
fluorescence polarization immunoassay, and then the dose to be administered was 
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designed so as to obtain a planned trough teicoplanin serum level of 15μg/ml , after 
estimating the volume of distribution (Vd) and the elimination constant (Kel), 
employing a two-compartment Bayesian population model 2).  The effect of 
teicoplanin was evaluated in terms of the clinical findings, laboratory data, and 
bacteriologic responses.  The classifications used were as follows: “excellent” for 
subjects with eradication of MRSA and improvement of clinical data, leukocyte counts, 
CRP, ESR, and infiltrative shadows on chest X-ray films; “good” for subjects with 
decreased MRSA and improvement of clinical data, leukocyte counts, CRP, ESR, and 
infiltrative shadows on chest X-ray films; and “poor” for subjects with persistent MRSA 
or no improvement in one of the following parameters: clinical data, leukocyte counts, 
CRP, ESR, or chest X-ray findings. 
  Creatinine clearance (Ccr, ml/min) in adult males was calculated according to the 
formula of Cockcroft and Gault 3):  
Ccr = (140-age) x (weight in kg) / 72 x (serum creatinine (mg/dl)) (15% less in 
females). 
     A significant change in laboratory data was defined as an increase of 120% or 
more from an upper limit of the normal range when data were normal before therapy or 
an increase of 200% or more from an abnormal data level before therapy.   
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Statistical analysis 
Data values are presented as means ± SD. One-way analysis of variance was used 
when multiple comparisons were made. Differences among groups were considered 
significant when P was less than 0.05. 
 
Results 
     Forty-eight patients were available for the retrospective analysis.  Figure 1 
shows the relationship between the clinical efficacy, patients' ages, and serum trough 
levels of teicoplanin before the 4th day administration.  The mean trough levels were; 
7.9 ± 4.7μg/ml in subjects with excellent responses; 8.2 ± 4.7μg/ml in those with 
good responses; 6.5 ± 3.0μg/ml in those with poor responses.  No subject had a 
trough level over 20μg/ml.  Twenty-two (45.8%) subjects had an excellent response; 
14 (29.2%) had a good response, and 12 (25.0%) had a poor response.  Subjects with a  
poor response had the lowest mean trough level.  Differences in trough levels between 
age groups (patients aged < 65 years, patients aged > 65 and < 80, and patients aged ≧
80 years) were not significant. 
Figure 2 shows the administered doses of teicoplanin and trough levels in six 
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patients suffering from renal dysfunction.  In cases 1, 2, 3, and 4 who had a loading 
dose of 400 mg, followed by 200 mg, the trough levels (before the injection on the 3rd 
day in case 1 and before the injection on the 4th day in case 2, 3, and 4) were 7.0μg/ml, 
6.5μg/ml, 4.6μg/ml, and 3.6μg/ml, respectively.  Hence, it seemed that even in 
subjects with renal dysfunction, a loading dose of 400 mg followed by a maintenance 
dose of 200 mg were not enough to attain the recommended trough level of 10 to 15μ
g/ml.  In contrast, as seen in case 5, who received an initial dose of 800 mg, and then 
400 mg on the 2nd and 3rd days, the trough level before the 4th day reached 18.2μg/ml.  
Case 6, who was treated for 7 days with 200 mg of teicoplanin daily, had an appropriate 
trough level.   In case 2, the serum concentrations of teicoplanin before and after HD 
were 5.6μg/ml and 4.9μg/ml, and elimination by HD seemed to be minimal, as has 
been reported by others 4)5).  
These findings raised the question as to whether the loading dose of 400 mg and 
the successive maintenance dose of 200 mg might be insufficient.  Thus, we focused 
on the relationship between the mean dose for the first 3 days (mean initial dose: MID), 
and the trough level before the 4th day.  The MID was calculated as follows: (loading 
dose + dose on 2nd day + dose on 3rd day) / 3.  In most subjects, the MIDs were given 
as (400 + 200 + 200) / 3 = 266.7 mg or (800 + 400 + 400) / 3 = 533.3 mg.  
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The mean MIDs were 359.4mg in those with excellent responses, 337.8mg in those with 
good responses, and 297.0mg in those with poor responses.  
     As illustrated in Fig.3, the trough levels at the point before the 4th day of 
administration (Cpre) in the 48 patients were closely correlated with a higher MID 
(r=0.7157).  In all but 1 of the patients with MID of 266.7 mg or less, the trough level 
before the 4th day did not exceed 10μg/ml.  On the other hand, most patients with an 
MID higher than 533.3 mg showed significantly elevated trough levels (p=0.0003).  
With respect to the clinical outcome, patients with trough levels (Cpre) lower than 10μ
g/ml tended to have poor outcomes. 
     To investigate the influence of renal function on the trough levels before the 4th 
day administration (Cpre), we compared the relation between the trough levels, Ccr, and 
the MID (Fig.4).  The Ccr data were obtained from 40 patients.   In patients with the 
same range of MID, those with a higher Ccr tended to show lower trough levels.  No 
dependence of trough levels on the presence or absence of HD was recognized (Fig.4).  
A multiple regression analysis formula for predicting trough level before the 4th day of 
administration is given as: 0.034 + 0.030 x MID (mg) -0.057 x Ccr (ml/min). 
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Table 1 summarizes the incidence of abnormal laboratory data in the 48 patients.  
Elevation of creatinine (Crt) and blood urea nitrogen (BUN) was observed in 2 (4.2%) 
and 4 patients (8.3%), respectively. Ten patients (20.8%) had an elevation of aspartate 
aminotransferase (AST), or alanine aminotransferase (ALT), or alkaline phosphatase 
(ALP).  No significant differences in the frequencies of abnormal laboratory data were 
noted between patients with and without HD.  No association between the total doses 
used and the incidence of abnormal data was found (data not shown).   No major 
complications were observed in any patient.   
     The intensification of the initial dose was found to cause an increase in the trough 
level before the 4th day (Cpre) , thereby possibly resulting in a good outcome, as seen 
in Fig. 3, although this intensification could possibly lead to a higher frequency of 
abnormal laboratory findings or adverse reactions.   In this regard, however, there was 
no relation between the incidence of abnormal laboratory findings and the MID (Table 
2). 
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Discussion 
     The glycopeptide antibacterial drugs, vancomycin and teicoplanin, are widely 
used for the therapy of infections caused by severe or multi drug-resistant gram-positive 
bacteria.  It is known that vancomycin has a narrow therapeutic range, and its 
pharmacokinetics - volume of distribution and clearance - are considerably affected by 
the host’s condition.  Therapeutic drug monitoring (TDM) has, therefore, been 
employed to determine the optimal dose, thus decreasing the incidence of side effects 
and enhancing the cost-effectiveness.  Teicoplanin, however, has some advantages 
over vancomycin, in that it has less potential for nephrotoxicity and histamine release 5).  
Monitoring of the serum level of vancomycin is mandatory in all patients for safety 
reasons.   For teicoplanin, this monitoring is recommended only in patients who are 
hemodynamically unstable, and in patients with serious infections 6).   Wood has 
reported that the monitoring of teicoplanin serum concentration is needed only to ensure 
that a therapeutic concentration is achieved 1). 
     In this context, we performed TDM to design an individual administration 
regimen for teicoplanin.  Patients with poor responses were found to have the lowest 
mean trough levels, and even in some patients with renal dysfunction, the loading dose 
of 400 mg followed by maintenance doses of 200 mg did not guarantee the 
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recommended serum concentration; that is, a trough level of 10-15μg/ml.   We 
focused on the relationship between the mean dose for the first 3 days (MID) and the 
trough level before the 4th day, and clinical efficacy.  When the MID, calculated as the 
total dose over the first 3 days / 3, was 266.7 mg or less, the trough level before the 4th 
day did not exceed 10μg/ml, which means this dose regimen is inappropriate for 
initiating therapy for infections.   
     Several studies have investigated the relationship between serum concentrations 
of glycopeptides and outcomes 7).  The pre-dose serum concentrations are useful in 
predicting clinical outcome 8).   Bantar et al. enrolled 15 patients to assess the efficacy 
of teicoplanin, 6mg/kg given daily during the first 3 days and then on alternate days, for 
the treatment of MRSA infections.  The mean serum levels of teicoplanin were 22, 8 
and 6.7μg/ml for the peak and the 24-h and 48-h troughs, respectively.  The dosage 
employed in that study proved effective for the treatment of soft tissue and 
catheter-associated infections 9).   Harding et al. showed that the two most readily 
quantifiable factors that influenced outcome were the mean predose serum 
concentration and the patient’s age - that is, the probability of successful treatment 
increased with predose serum concentration and decreased with age 8).   MacGowan 
et al. precisely reviewed 12 reports; 6 studies in which a 200 mg/day maintenance dose 
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of teicoplanin was used, and 6 studies with a 400 mg/day maintenance dose.  The 
mean trough levels in the former 6 studies did not exceed 10μg/ml in the first 7 days.  
In the latter 6 studies, the mean trough levels ranged from 4 to 11μg/ml on days 1-2, 9 
to 17μg/ml on days 6-7 of therapy.  In 5 of these studies, the mean trough levels were 
less than 10μg/ml on days 1-2.  MacGowan et al. concluded that trough levels and 
post-dose teicoplanin concentrations may be related to clinical outcomes 10).  A 
logistic regression analysis from the same group demonstrated that the probability of 
successful treatment with teicoplanin declined with age and increased with the mean 
predose serum concentration.  
     Glycopeptide antibacterial agents such as teicoplanin are known to show no 
concentration-dependent killing; this emphasizes the importance of trough levels, 
because the trough level is closely related to time above the minimum inhibitory 
concentration (MIC).  Transient high peak serum concentrations of teicoplanin are not 
likely to be of benefit in killing bacteria or curing infection.   On the other hand,  
sustained concentrations over the MIC were said to be of benefit in terms of improving 
extravascular drug penetration and cure rates 11).   Craig recently reported that the 
24-h AUC-MIC is probably the most important pharmacokinetic-pharmacodynamic 
(PK-PD) parameter correlated with the efficacy of vancomycin and teicoplanin 12).   
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Additional studies are needed to clarify further the pharmacodynamics of teicoplanin.   
In general, the initial period of therapy is of critical importance in treating infections 
with teicoplanin.   In the present study, patients treated with MID of 266.7mg or less 
(400mg for loading, 200mg over the 2nd and 3rd days) did not reach the 10μg/ml 
trough level, while most patients treated with an MID greater than 533.3mg (800mg for 
loading, 400mg over the 2nd and 3rd days) had significant trough levels.  Even in the 
patients with renal dysfunction, the trough levels were appropriate when they were 
treated with an MID greater than 533.3mg.    
     For teicoplanin, there are data linking the predose concentrations to the toxicity of  
thrombocytopenia 7).   Thus, increases in the trough and/or MID values may cause 
higher incidences of abnormal data.   However, in the present study, no relation was 
found between abnormal data and MID levels of 533.3mg or less.   Bibler et al. 
showed that the most significant adverse reaction to teicoplanin was an urticarial rash, 
which required discontinuation of therapy in one patient.   Pruritus, rash, eosinophilia, 
and transaminase elevation have been reported occasionally 13). 
    We conclude that, for teicoplanin, 800mg as an initial dose, followed by 400mg for 
2 days can be recommended to promptly and safely obtain an optimal trough level. 
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Legends for Figures 
 
 
 
 
 
 
Fig1: The relationship between the clinical efficacy, patients’ ages, and serum trough levels of 
teicoplanin before the 4th day of administration. HD, hemodialysis 
 
 
 
 
 
 
 
 
 
Fig2: Administered doses of teicoplanin and their trough levels (narrow arrow) and the serum 
concentrations 2h after administration (thick arrow) in six patients with renal dysfunction. 
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Fig3: Trough levels of teicoplanin at the point before the 4th day of administration (Cpre) in 48 
patients, mean initial dose (MID), and efficacy.   Crosses show poor response; triangles, good 
response; and dots, excellent response.   See text for definition of efficacy.  Cpre values were 
closely correlated with higher MID. 
 
 
 
 
 
 
 
 
Fig4: The relation between trough levels of teicoplanin before the 4th day of  administration 
(Cpre), creatinine clearance (Ccr) in 40 patients and the MID.   Circles, MID ≦200mg; dots,
＞200 to ≦300mg; triangles, ＞300 to ≦400mg; asterisks, ＞400 to ≦800mg. 
 
